To follow changes in bone mineral density (BMD) over time when Myfembree is used for up to 4 years. Also to follow BMD for 1 year after treatment is stopped.
Currently, this medicine is approved by the United States (US) Food and Drug Administration (FDA) for up to 2 years of use for the management of premenopausal women with moderate to severe pain associated with endometriosis. The sponsor is investigating if this medication can be taken for 4 years. This study looks at the medication's effect on bone (BMD) and your body over the four years of treatment and for one year after treatment stops.
-Premenopausal women 18-50 years with a diagnosis of endometriosis -Premenopausal women 18-50 years with a diagnosis of endometriosis -Not pregnant and willing to avoid pregnancy for 4 years -has a BMI greater than 18 kg/m2 -have a Vitamin D level higher than 12ng/mL -No history of low trama facture -No history of gastric surgery -Normal mammogram -No current breast cancer
Principal Investigator